Alzamend Neuro, Inc.
Alzamend Neuro, Inc. (ALZN): 4 pipeline candidates · ~5 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
5.2 months
D/E 0.85 · 0% dilution
Lead: Phase 1/Phase 2
4 candidates
N/A
1 buy · 1 sell (180d)
A transparent, data-derived signal for Alzamend Neuro, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$4.7M
Cash
$2.7M
Quarterly Burn
$1.7M
Runway
5.2 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| Additional AL001 License | Phase 1/Phase 2 |
| AdditionalAL001 | Phase 1/Phase 2 |
| AL001 | Phase 1/Phase 2 |
| ALZN002 | — |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
8
Total value held
$105K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 45,680 | $48K |
| vanguard fiduciary trust co | 21,020 | $22K |
| morgan stanley | 18,000 | $19K |
| vanguard capital management llc | 8,800 | $9K |
| citigroup inc | 5,231 | $6K |
| blackrock, inc. | 437 | $463 |
| caitong international asset management co., ltd | 4 | $4 |
| harbor investment advisory, llc | 1 | $1 |
Frequently asked questions
How many drug candidates are in Alzamend Neuro, Inc.'s pipeline?
Alzamend Neuro, Inc. (ALZN) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Alzamend Neuro, Inc.'s lead drug candidate?
Alzamend Neuro, Inc.'s most advanced tracked candidate is Additional AL001 License (Phase 1/Phase 2) for Bipolar I Disorder.
What is Alzamend Neuro, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Alzamend Neuro, Inc. has approximately 5.2 months of cash runway.
What is Alzamend Neuro, Inc.'s market capitalization?
Alzamend Neuro, Inc.'s market capitalization is approximately $4.7M.
Who is the CEO of Alzamend Neuro, Inc.?
Mr. Stephan Jackman is the chief executive officer of Alzamend Neuro, Inc. (ALZN).
Get the full picture on Alzamend Neuro, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.